CTMX Healthcare

CytomX Therapeutics, Inc.

$2.18-2.24%

Price as of close on Nov 3, 2026 · Financials updated Oct 8, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 475.0M USD
Enterprise value: 150.4M USD
Full-time employees: 69

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 2.20 vs a peer median of 0.63)bigger price swings (beta 2.20 vs peers 0.63)

Ranks #1,092 of 1,157 healthcare companies (bottom 6%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 229% from December 2022 to July 2026.
CytomX Therapeutics had 229% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.CytomX Therapeutics had 229% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Earnings slid into a loss. Loss per share this year after a profit last year.
CytomX Therapeutics made a loss per share in its latest year after a profit the year before.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, CytomX Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
CytomX Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

22/ 100

Oct 5 22 → Nov 4 22

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-16.8%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-57.3%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-17.4%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield63.6%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

3/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

12-month revenue fell 48.5%

Why

Weaker than most peers on:

▼ 3-yr revenue
▼ Revenue growth
▼ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a profit to a loss33% base weight · Z-score -1.99Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth-38.7%

SEC filings · 3 years to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -3.70Sector median: 0.0584 · MAD: 0.0840

Revenue growth-87.0%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -4.87Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

7/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-476.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -39.70Sector median: 0.0706 · MAD: 0.1217

Return on assets-20.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.20Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-24.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.88Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin100.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-26.4%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta2.20

Yahoo Finance · 5-year monthly beta vs the marketOutlier capped at sector 5th/95th percentile33% base weight · Z-score -4.28Sector median: 0.6250 · MAD: 0.3380

Current ratio9.36×

SEC filings · latest balance sheetReported value33% base weight · Z-score 4.89Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.02×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.99Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about CytomX Therapeutics

Is CytomX Therapeutics getting weaker?: Its latest SEC filing (Aug 6, 2026) got weaker in some ways: 12-month revenue fell 48.5%. Its overall score is unchanged at 22/100 since Oct 28, 2026.
How is CytomX Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -16.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -16.8% vs peers 1.5% (weaker than 100% of peers).
Is CytomX Therapeutics growing?: More slowly than most of its peers. Growth scores 3/100 against 1,393 healthcare peers. 3-year revenue growth -38.7% vs a peer median of 5.8% (weaker than 100% of peers).3-year revenue growth -38.7% vs peers 5.8% (weaker than 100% of peers).
How profitable is CytomX Therapeutics?: Less profitable than most of its peers. Profitability scores 7/100 against 1,393 healthcare peers. Operating margin -476.2% vs a peer median of 7.1% (weaker than 93% of peers).Operating margin -476.2% vs peers 7.1% (weaker than 93% of peers).
How risky is CytomX Therapeutics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 9.36× vs a peer median of 2.59× (stronger than 86% of peers).Current ratio 9.36× vs peers 2.59× (stronger than 86% of peers). Beta 2.20 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.20 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 6, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

12-month revenue fell 48.5%

Worth watching: CytomX Therapeutics is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	35.5M USD	18.3M USD	−48.5%
Net income (12 months)	−59.1M USD	−79.7M USD	+34.7%
Operating margin	-181.9%	-476.2%	−294.3 pts
Free cash flow (12 months)	−80.2M USD	−82.5M USD	+2.9%
Cash	28.8M USD	17.2M USD	−40.3%
Shares outstanding	217.7M	217.9M	+0.1%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	-311.0%	-190.6%	-6.4%	18.1%	-29.3%	▼ 47 pts
Net margin	-310.5%	-186.8%	-0.6%	23.1%	-22.8%	▼ 46 pts
Return on assets (ROA)	-34.1%	-38.1%	-0.3%	26.4%	-11.5%	▼ 38 pts
Return on equity (ROE)	—	—	—	—	-17.5%	—
Free cash flow margin	-323.3%	-211.7%	-56.2%	-62.7%	-99.5%	▼ 37 pts
Current ratio	3.98×	1.55×	1.17×	1.25×	3.09×	▲ 147%

CTMX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 2.20 vs a peer median of 0.63)bigger price swings (beta 2.20 vs peers 0.63)

Ranks #1,092 of 1,157 healthcare companies (bottom 6%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 229% from December 2022 to July 2026.

CytomX Therapeutics had 229% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.CytomX Therapeutics had 229% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Earnings slid into a loss. Loss per share this year after a profit last year.

CytomX Therapeutics made a loss per share in its latest year after a profit the year before.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, CytomX Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

CytomX Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about CytomX Therapeutics

Is CytomX Therapeutics getting weaker?

Its latest SEC filing (Aug 6, 2026) got weaker in some ways: 12-month revenue fell 48.5%. Its overall score is unchanged at 22/100 since Oct 28, 2026.

How is CytomX Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -16.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -16.8% vs peers 1.5% (weaker than 100% of peers).

Is CytomX Therapeutics growing?

More slowly than most of its peers. Growth scores 3/100 against 1,393 healthcare peers. 3-year revenue growth -38.7% vs a peer median of 5.8% (weaker than 100% of peers).3-year revenue growth -38.7% vs peers 5.8% (weaker than 100% of peers).

How profitable is CytomX Therapeutics?

Less profitable than most of its peers. Profitability scores 7/100 against 1,393 healthcare peers. Operating margin -476.2% vs a peer median of 7.1% (weaker than 93% of peers).Operating margin -476.2% vs peers 7.1% (weaker than 93% of peers).

How risky is CytomX Therapeutics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 9.36× vs a peer median of 2.59× (stronger than 86% of peers).Current ratio 9.36× vs peers 2.59× (stronger than 86% of peers). Beta 2.20 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.20 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

35.5M USD

18.3M USD

−48.5%

Net income (12 months)

−59.1M USD

−79.7M USD

+34.7%

Operating margin

-181.9%

-476.2%

−294.3 pts

Free cash flow (12 months)

−80.2M USD

−82.5M USD

+2.9%

Cash

28.8M USD

17.2M USD

−40.3%

Shares outstanding

217.7M

217.9M

+0.1%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

-311.0%

-190.6%

-6.4%

18.1%

-29.3%

▼ 47 pts

Net margin

-310.5%

-186.8%

-0.6%

23.1%

-22.8%

▼ 46 pts

Return on assets (ROA)

-34.1%

-38.1%

-0.3%

26.4%

-11.5%

▼ 38 pts

Return on equity (ROE)

—

-17.5%

—

Free cash flow margin

-323.3%

-211.7%

-56.2%

-62.7%

-99.5%

▼ 37 pts

Current ratio

3.98×

1.55×

1.17×

1.25×

3.09×

▲ 147%